Direct oral anticoagulants such as direct factor Xa inhibitors are now commonly prescribed to manage patients with blood clotting disorders. The main advantage of this class of medication is free of routine monitoring in non-complicated patients. However, the complex pharmacokinetic profiles of special populations can complicate the dosing regimen of the oral anticoagulants. Currently, surrogate tests with coagulation markers, liquid chromatography, and thrombin generation assay can be used to determine the specific serum level of the drug. However, these tests are either non-specific or labor and cost-intensive. Direct measurement of the drug level with specific molecular recognition elements may benefit the unique needs of complicated patients. This study focuses on the identification of a single-stranded DNA (ssDNA) aptamer that binds to a direct factor Xa inhibitor. In this study, we use a graphene oxide and microwell-plate based combined approach to identify an aptamer that binds to the target with high affinity and specificity. This combined <i>in-vitro</i> selection approach can be easily adapted to most molecules that are reasonably soluble in aqueous solution. Ultimately, it will allow us to incorporate the aptamer into a proof-of-concept biosensing platform.

Identification of ssDNA specific to a direct factor Xa inhibitor

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.